Idorsia Ltd (IDRSF)
OTCMKTS
· Delayed Price · Currency is USD
1.000
-0.050 (-4.76%)
At close: Apr 7, 2025
Idorsia Revenue
Idorsia had revenue of 58.88M CHF in the quarter ending March 31, 2025, with 485.38% growth. This brings the company's revenue in the last twelve months to 161.33M, up 14.08% year-over-year. In the year 2024, Idorsia had annual revenue of 112.51M, down -26.17%.
Revenue (ttm)
161.33M CHF
Revenue Growth
+14.08%
P/S Ratio
2.83
Revenue / Employee
248.20K CHF
Employees
650
Market Cap
351.20M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
| Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
| Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
| Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
| Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Idorsia News
- 5 weeks ago - Idorsia publishes its Annual Report 2024 - GlobeNewsWire
- 6 weeks ago - Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia - GlobeNewsWire
- 2 months ago - Idorsia Ltd (IDRSF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Idorsia Ltd 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Idorsia announces financial results for 2024 - GlobeNewsWire
- 2 months ago - Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call - GlobeNewsWire
- 2 months ago - Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations - GlobeNewsWire
- 2 months ago - Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties - GlobeNewsWire